RTX-100

RTX-100 is a preclinical-stage antibody therapeutic being developed by Resonant Therapeutics for the treatment of breast cancer and liver cancer. Discovered through Resonant's proprietary platform, which identifies novel, highly selective tumor targets within the tumor microenvironment, RTX-100 is directed against a matrix receptor. Matrix receptors are a class of proteins involved in the interaction between cancer cells and the extracellular matrix, playing critical roles in tumor growth, invasion, and metastasis. While the specific molecular identity of the target has not been publicly disclosed by the developer, the drug is designed to disrupt tumor-promoting signals or potentially serve as a vehicle for delivering therapeutic payloads to the tumor site.